Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 12209138
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: January 28, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 12209124
    Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: January 28, 2025
    Assignees: Shanghai Junshi Biosciences Co., Ltd., Suzhou Junmeng Biosciences Co., Ltd.
    Inventors: Jian Yao, Dan Meng, Hui Feng, Sheng Yao, Hai Wu
  • Patent number: 12202903
    Abstract: This invention relates to humanised versions of the murine anti-IL17BR antibody D9.2 which comprise mutations of certain residues within the heavy chain and/or light chain variable domains that display improved expression without deleterious effects on specificity or affinity. The humanised antibodies may comprise a heavy chain variable (VH) domain which comprises a VHCDR1 of SEQ ID NO: 1, a VHCDR2 of SEQ ID NO: 2, and a VHCDR3 of SEQ ID NO: 3, for example, a VH domain of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. The humanised antibodies may comprise a light chain variable (VL) domain which comprises a VLCDR1 of SEQ ID NO: 4, a VLCDR2 of SEQ ID NO: 5, and a VLCDR3 of SEQ ID NO: 6, for example a VL domain of SEQ ID NO: 13. Antibodies, pharmaceutical compositions and methods of use, for example in the treatment of cancer are provided.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: January 21, 2025
    Assignee: LIFEARC
    Inventors: Seema Patel, David Matthews
  • Patent number: 12202878
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 21, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Gisela Schimmack, Michael Roemer
  • Patent number: 12195549
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: January 14, 2025
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Patent number: 12195547
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: January 14, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katharina Lechner, Thomas Francis Moore, Martin Weisser, Natalie Dimier, David John Carlile, Nassim Djebli, Peter Nabil Morcos, Linda Maria Lundberg
  • Patent number: 12187802
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 7, 2025
    Assignee: Stemline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Patent number: 12187794
    Abstract: The present disclosure generally relates to compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: January 7, 2025
    Assignee: AlaMab Therapeutics, Inc.
    Inventor: Yanfeng Zhang
  • Patent number: 12174612
    Abstract: Estimating or predicting runnability or end product quality risk level for a pulp or papermaking process is disclosed. The method includes measuring hydrophobicity values of samples originating from a same aqueous process stream. A hydrophobicity measurement signal is produced of measured hydrophobicity values as a function of time. A risk level is calculated for the process. At least one mathematical index is calculated based on the hydrophobicity measurement signal, and optionally based on the amount of particles in the sample, other property of the aqueous stream and/or production data. The mathematical index and optionally the amount of the particles, other property, and/or production data is used as a risk indicator input in the calculation. Based on the risk level calculated for the pulp or papermaking process, the runnability and/or end product quality risk level for the pulp or papermaking process is indicated.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: December 24, 2024
    Assignee: Kemira Oyj
    Inventors: Iiris Joensuu, Marjatta Piironen
  • Patent number: 12173058
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: December 24, 2024
    Assignee: Mereo Biopharma 3 Limited
    Inventors: Uwe Junker, Michaela Kneissel, Anthony Kent Hall, Rena Joy Eudy, Matthew Manning Riggs
  • Patent number: 12173083
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: December 24, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
  • Patent number: 12168698
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: December 17, 2024
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 12161712
    Abstract: Provided herein are non-naturally occurring, broadly reactive, pan-epitopic antigens derived from H3 influenza virus that are immunogenic and are capable of eliciting a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against H3 virus following introduction into a subject. Also provided are non-naturally, broadly reactive occurring immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise the hemagglutinin (HA) protein of H3 influenza virus strains.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: December 10, 2024
    Assignee: University of Georgia Research Foundation
    Inventors: James Daniel Allen, Ted Milburn Ross, Terianne Maiko Wong
  • Patent number: 12144851
    Abstract: The present invention relates to the prevention and treatment of disease like cancer. The inventors have previously characterized MELOE-1 antigen as an IRES dependent, melanoma specific translation product from a lncRNA mainly transcribed in the melanocytic lineage. MELOE-1 contains numerous class II epitopes and one HLA-A*0201-restricted CD8 epitope eliciting a frequent repertoire of high avidity T cells. They designed various synthetic long peptide (SLPs) comprising a CD4 epitope coupled to the CD8 epitope by a serie of linkers of 4 to 6 aa and studied the efficacy of T cell clone activation by SLP-loaded DC in vitro. Particularly, they evaluated the ability of a few selected SLPs to stimulate specific T cells proliferation of PBL from healthy donors in vitro and finally, they explored the vaccination potential of their best SLP candidate in vivo in an HLA*A0201/HLA-DRB0101 transgenic mouse.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 19, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
    Inventors: François Lang, Catherine Rabu
  • Patent number: 12146138
    Abstract: A method of treating an inflammatory disorder in a subject, comprising administering to a subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: November 19, 2024
    Inventors: Zhenglun Zhu, Hong Gao
  • Patent number: 12145998
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: November 19, 2024
    Assignee: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 12140594
    Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: November 12, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE CLAUDÉBERNARD—LYON 1, CENTRE LEON BERARD, KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)
    Inventors: Kim In-San, Philippe Bertolino, Ana Hennino
  • Patent number: 12139532
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: November 12, 2024
    Assignees: ImmuNext, Inc., THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jay Rothstein, Isabelle Lemercier, Linda Snyder, Gordon Powers
  • Patent number: 12133843
    Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of secondary bacterial infections, preferably secondary respiratory infections.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: November 5, 2024
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Laura Brandolini, Marcello Allegretti, Mauro Martins Teixeira
  • Patent number: 12134646
    Abstract: The present invention relates to a novel anti-C-KIT antibody or an antibody fragment thereof. In addition, the present invention relates to a composition for preventing or treating angiogenesis-related diseases comprising the anti-C-KIT antibody or an antibody fragment thereof, or a kit for diagnosing angiogenesis-related diseases.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: November 5, 2024
    Assignee: NOVELTY NOBILITY INC.
    Inventors: Sang Gyu Park, Jin-Ock Kim
  • Patent number: 12134651
    Abstract: Methods for inhibiting degeneration of a neuron, methods of treating a neurological/neurodegenerative disease, methods of modulating the directional growth of a neuron, and methods of interfering with the interaction of Wnt and Ryk are provided herein. Also provided are isolated anti-Ryk antibodies and antibody fragments that specifically bind to a binding domain of Wnt.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 5, 2024
    Assignee: The Regents of the University of California
    Inventor: Yimin Zou
  • Patent number: 12129307
    Abstract: Monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: October 29, 2024
    Assignee: MAB Discovery GmbH
    Inventors: Stephan Fischer, Michael Brandt
  • Patent number: 12129285
    Abstract: A method of treating a neurodegenerative disease in a subject includes administering to the subject a therapeutically effective amount of a TDP-43 mitochondrial localization inhibitor.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: October 29, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Xinglong Wang
  • Patent number: 12097248
    Abstract: A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: September 24, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Patent number: 12084486
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Gisela Schimmack, Michael Roemer
  • Patent number: 12084514
    Abstract: CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 10, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Courtney W. Houchen
  • Patent number: 12076380
    Abstract: A peptide consists of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: September 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Patent number: 12077599
    Abstract: The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 3, 2024
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NATIONAL CANCER CENTER, THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
    Inventors: Junho Chung, Eugene C. Yi, Ji Eun Kim, Hwa Kyoung Lee, Junyeong Jin, Jong Bae Park, Hyori Kim
  • Patent number: 12071666
    Abstract: The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets Clostridium difficile (C. difficile) toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment that targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 27, 2024
    Assignees: Merck Sharp & Dohme LLC, Beijing Genomics Institute at Shenzhen
    Inventors: Peter M. Shaw, Devan V. Mehrotra, Rebecca L. Blanchard, Judong Shen, Robin Mogg, Mary Beth Dorr, Junhua Li, Xun Xu
  • Patent number: 12043671
    Abstract: Antibodies and antibody-drug conjugates that selectively bind to a membrane-associated extracellular portion of a cleaved amphiregulin precursor protein; methods of using the antibodies and antibody-drug conjugates to detect and inhibit the growth of neoplastic cells; pharmaceutical compositions containing the antibodies and/or antibody-drug conjugates as the active ingredient(s); kits containing the antibodies and/or antibody-drug conjugates.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 23, 2024
    Assignee: Gundersen Lutheran Medical Foundation, Inc.
    Inventors: Paraic Anthony Kenny, Kristopher Andrew Lofgren, Sreeja Sreekumar
  • Patent number: 12037406
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 16, 2024
    Assignee: Eli Lilly and Company
    Inventors: Carmine Carpenito, Yiwen Li
  • Patent number: 12024546
    Abstract: A peptide according to an embodiment may be used as an anti-cancer agent. The peptide has a binding activity to fibronectin and competitively binds to fibronectin with dysadherin. Therefore, the peptide may be used to prevent binding between dysadherin in a cell membrane of cancer cells and fibronectin in ECM, and may be used as an anti-cancer agent to weaken survival, migration or invasion of cancer cells.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: July 2, 2024
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jeong Seok Nam, So Yeon Park, Tae Young Jang
  • Patent number: 12006369
    Abstract: The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: June 11, 2024
    Assignee: 2seventy bio, Inc.
    Inventors: Richard Morgan, Kevin Friedman
  • Patent number: 12005081
    Abstract: Provided herein are acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: June 11, 2024
    Assignee: Senti Biosciences, Inc.
    Inventors: Brian Scott Garrison, Jennifer Chien, Kathryn Armstrong Loving, Russell Morrison Gordley, Michelle Elizabeth Hung
  • Patent number: 11993641
    Abstract: The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
    Type: Grant
    Filed: July 27, 2023
    Date of Patent: May 28, 2024
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11970529
    Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: April 30, 2024
    Assignee: Hefei Lifeon Pharmaceutical Co., Ltd.
    Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
  • Patent number: 11965029
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: April 23, 2024
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • Patent number: 11944596
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: April 2, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Patent number: 11946935
    Abstract: Methods and diagnostic compositions for detecting and monitoring meningiomas.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: April 2, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Nurten Saydam, Okay Saydam
  • Patent number: 11939387
    Abstract: The present invention discloses an antibody capable of binding to human interleukin 4 receptor alpha (hIL-4R alpha) and a preparation method and application thereof. The anti-hIL-4R alpha antibody can specifically bind to hIL-4R alpha, has good effects for inhibiting IL-4 and IL-13-induced cell line proliferation and the like, and can be applied to treatment of IL-4R alpha related diseases, such as immune-mediated inflammatory diseases.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: March 26, 2024
    Assignee: SHANGHAI MABGEEK BIOTECH. CO., LTD
    Inventors: Chenghai Zhang, Jinlin Guo, Yujing Yuan
  • Patent number: 11911357
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: February 27, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Patent number: 11912769
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: February 27, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Patent number: 11896667
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: February 13, 2024
    Assignee: UCB PHARMA S.A.
    Inventor: Martyn K. Robinson
  • Patent number: 11891446
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: February 6, 2024
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • Patent number: 11892450
    Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: February 6, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kusumam Joseph, Allen P. Kaplan
  • Patent number: 11884720
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: January 30, 2024
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
  • Patent number: 11873337
    Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 16, 2024
    Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
  • Patent number: 11866500
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 9, 2024
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
  • Patent number: 11866511
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 9, 2024
    Assignee: TigaTX, Inc.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers
  • Patent number: 11859002
    Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 2, 2024
    Assignee: The General Hospital Corporation
    Inventor: Denise L. Faustman